It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.

Provided are ex vivo and in vivo methods utilizing therapeutic genes for treatment of male and female infertility, including non-obstructive azoospermia (NOA) and premature ovarian insufficiency (POI) and comorbid diseases, with or without transmitting the therapeutic gene to offspring of the infertile subject. Germline gene therapy methods are also described to reduce or eliminate disease from families with or without transmission of the therapeutic gene to offspring.

A method of enhancing sperm fertility is described herein. The method includes contacting sperm with hydroxyurea. A composition is disclosed that includes sperm, hydroxyurea, and a buffer. Methods, kits, and compositions for enhancing sperm fertility are also provided.

A method of enhancing sperm fertility is described herein. The method includes contacting sperm with hydroxyurea. A composition is disclosed that includes sperm, hydroxyurea, and a buffer. Methods, kits, and compositions for enhancing sperm fertility are also provided.

The present invention is an exosome isolation method for obtaining high purity exosomes inexpensively from samples of large and small amounts and types of samples from which exosomes could not be obtained before such as plant lysates. The exosome isolation method incorporates a two phase fluid extraction system, and includes the steps of isolation using dextran and PEG for removing proteins and undesired substances therein, and the steps of washing and dextran removal to collect exosomes in a pure form.

The present invention is an exosome isolation method for obtaining high purity exosomes inexpensively from samples of large and small amounts and types of samples from which exosomes could not be obtained before such as plant lysates. The exosome isolation method incorporates a two phase fluid extraction system, and includes the steps of isolation using dextran and PEG for removing proteins and undesired substances therein, and the steps of washing and dextran removal to collect exosomes in a pure form.

The present invention relates to sustained release compositions, and in particular a sustained release composition comprising spermatozoa embedded in a matrix, such as a polymeric matrix. By having at least two sections with distinct dissolution rate, the matrix will ensure that spermatozoa are released for a prolonged period of time and thus making the time of insemination relative to ovulation less critical. Further, the present invention also relates to a method for preparing the sustained release composition, container comprising the sustained release composition and use of the sustained release composition in the breeding of animals.

The present invention relates to sustained release compositions, and in particular a sustained release composition comprising spermatozoa embedded in a matrix, such as a polymeric matrix. By having at least two sections with distinct dissolution rate, the matrix will ensure that spermatozoa are released for a prolonged period of time and thus making the time of insemination relative to ovulation less critical. Further, the present invention also relates to a method for preparing the sustained release composition, container comprising the sustained release composition and use of the sustained release composition in the breeding of animals.

A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.

A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.